Trueblood Wealth Management LLC Raises Stake in Perspective Therapeutics, Inc. $CATX

Trueblood Wealth Management LLC increased its stake in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 210.6% during the second quarter, according to its most recent filing with the SEC. The fund owned 69,061 shares of the company’s stock after buying an additional 46,825 shares during the quarter. Trueblood Wealth Management LLC owned 0.09% of Perspective Therapeutics worth $238,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Perspective Therapeutics by 19.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock worth $224,000 after buying an additional 11,472 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Perspective Therapeutics by 11.1% in the 1st quarter. Bank of New York Mellon Corp now owns 159,366 shares of the company’s stock valued at $339,000 after acquiring an additional 15,897 shares during the period. HighTower Advisors LLC raised its stake in Perspective Therapeutics by 13.2% in the 1st quarter. HighTower Advisors LLC now owns 201,586 shares of the company’s stock valued at $429,000 after acquiring an additional 23,475 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Perspective Therapeutics by 6.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company’s stock valued at $925,000 after acquiring an additional 27,119 shares during the period. Finally, Affinity Asset Advisors LLC raised its stake in Perspective Therapeutics by 71.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after acquiring an additional 924,196 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Stock Down 2.3%

Shares of CATX opened at $3.47 on Wednesday. Perspective Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $13.44. The company has a current ratio of 15.09, a quick ratio of 15.09 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $3.51 and its 200-day moving average price is $3.10.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Saturday, July 12th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Thursday, October 2nd. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Friday, October 3rd. Finally, B. Riley restated a “buy” rating and issued a $12.00 price objective (up from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and a consensus price target of $12.56.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.